Richard D. Francis - 05 Jun 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: President and CEO
Signature: /s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis
Issuer symbol: TEVA
Transactions as of: 05 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 09 Jun 2025, 16:01:33 UTC
Previous filing: 07 Mar 2025
Next filing: 29 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Francis Richard D	President and CEO	C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL	/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis	09 Jun 2025	0001673277

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Award	$0	+52,173		$0.000000	52,173	05 Jun 2025	Ordinary Shares	52,173		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2	Restricted share units were granted on June 5, 2025, with 13,043 vesting on each of June 5, 2026, June 5, 2027, and June 5, 2028 and 13,044 vesting on June 5, 2029.
F3	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.